Riboflaven and bilirubin response during phototherapy

Area of Science:

• Neonatal Medicine
• Biochemistry
• Photobiology

Background:

• Neonatal jaundice, a common condition, requires effective treatment to prevent complications.
• Phototherapy using blue light is a standard treatment for hyperbilirubinemia.
• Riboflavin (vitamin B2) is being investigated as an adjunct to phototherapy.

Purpose of the Study:

• To evaluate the efficacy of oral riboflavin in enhancing phototherapy for neonatal jaundice.
• To determine the effect of riboflavin on bilirubin levels during blue light treatment.
• To explore the relationship between blue light energy, riboflavin, and bilirubin reduction.

Main Methods:

• A randomized study of 24 jaundiced neonates, divided into treatment (riboflavin) and control groups.
• Phototherapy administered with blue light (420-470 nm) at varying energy levels (6-10 μW/cm²).
• Comparison of 24-hour bilirubin decrease in riboflavin-treated infants versus controls, considering light energy dose.

Main Results:

• Riboflavin-treated infants receiving lower blue light energy showed bilirubin decrease similar to controls.
• Infants receiving riboflavin with blue light energy equivalent to controls demonstrated a significantly greater bilirubin decline (5.2 mg/100 ml/24 hr).
• The study indicates a synergistic effect between riboflavin and phototherapy.

Conclusions:

• Oral riboflavin can enhance the effectiveness of phototherapy in reducing neonatal bilirubin levels.
• Further in vivo research is necessary to fully understand the implications of riboflavin as a photosensitizer, particularly concerning potential DNA effects.
• Riboflavin shows promise as an adjunctive therapy for neonatal hyperbilirubinemia.